A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) (NCT07268638)

🧪 Interventions in This Study

• Praliciguat (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. UPCR ≥1 (g/g) during screening.
2. On maximally tolerated ACEi or ARB per principal investigator discretion within 1 month of informed consent.
3. Estimated glomerular filtration rate ≥25 milliliters per minute per 1.73 square meters by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
4. Kidney biopsy collected within 5 years of screening consistent with FSGS or kidney biopsy collected ≥5 years prior to screening consistent with FSGS plus the presence of a pathogenic gene mutation known to be associated with FSGS.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (25 Sites)

• Investigator Site #2 — Chula Vista, California
• Investigator Site #14 — Los Angeles, California
• Investigator Site #12 — San Dimas, California
• Investigator Site #13 — Arvada, Colorado
• Investigator Site #17 — Boca Raton, Florida
• Investigator Site #6 — Coral Springs, Florida
• Investigator Site #25 — Hialeah, Florida
• Investigator Site #7 — Miami, Florida
• Investigator Site #8 — Orlando, Florida
• Investigator Site # 1 — Lawrenceville, Georgia
• Investigator Site #3 — Chicago, Illinois
• Investigator Site #11 — Louisville, Kentucky
• Investigator Site #24 — Worcester, Massachusetts
• Investigator Site #15 — Livonia, Michigan
• Investigator Site #10 — Pontiac, Michigan
• Investigator Site #16 — New Bern, North Carolina
• Investigator Site #20 — Cleveland, Ohio
• Investigator Site #19 — Bridgeville, Pennsylvania
• Investigator Site #22 — Butler, Pennsylvania
• Investigator Site #23 — Goose Creek, South Carolina
• Investigator Site #4 — Chattanooga, Tennessee
• Investigator Site #5 — Arlington, Texas
• Investigator Site #21 — Dallas, Texas
• Investigator Site #9 — Dallas, Texas
• Investigator Site #18 — Houston, Texas

📞 Contact the Study Coordinator

Phone: (617) 844-6128

Email: trials@akebia.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
• 💵 Compensation indicated: Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.

More studies in Focal Segmental Glomerulosclerosis

• An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases — Bethesda, Maryland
• Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children — Loma Linda, California
• Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System — Loma Linda, California
• Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases — Los Angeles, California
• Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease — Ann Arbor, Michigan

Explore by condition: All Focal Segmental Glomerulosclerosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.